1 / 14

Depth of Anaesthesia Monitoring : What’s validated and What’s next?

Depth of Anaesthesia Monitoring : What’s validated and What’s next?. British Journal of Anaesthesia 2006 R4 최 정 현. new surgical procedure increasing prevalence of day surgery ‘value for money’  influence the choice of drug and techniques for anesthesia

nasya
Télécharger la présentation

Depth of Anaesthesia Monitoring : What’s validated and What’s next?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Depth of Anaesthesia Monitoring: What’s validated and What’s next? British Journal of Anaesthesia 2006 R4 최 정 현

  2. new surgical procedure • increasing prevalence of day surgery • ‘value for money’  influence the choice of drug and techniques for anesthesia • Anesthesia (balance) • Amount of anesthetic drug  state of arousal • Equipment failure, error  underdosing • Inappropriate titration  excessive DoA(depth of anesthesia)  compromise patient outcome

  3. Patient movement to noxious stimulation : important sign of inadequate DoA but unreliable, suppressed by paralysis • Traditional clinical sign(HTN, tachycardia, lacrimation)  unreliable • Reliable DoA monitor have been developed • Early : raw or summate EEG, lower esophageal contractility  unreliable • Isolated forearm technique : not been widely adopted • Useful comparator in the evaluation of newer method • AEP(Auditory-evoked potential) : clear dose-response • Bispectral index (BIS) • Spectral entropy • Typically scaled from 100 (awake) to 0 (deep coma)

  4. Do we need DoA monitors? • Patient experienced awareness  traumatized, anxious • Incidence

  5. Do we need DoA monitors? • Larger than adequate dose for avoiding awareness  risk of hypotension, delay recovery time, increase other complications • Monk and collegues : • Significant independent predictors of mortality • Three variables • Patient co-morbidity • Cumulative deep hypnotic time (BIS<45) • Intraop sys. hypotension

  6. What DoA monitoring technologies are available? • Spontaneous EEG & MLAEP (Mid-latency auditory-evoked response)  information about the hypnotic state • Fast few years • EEG-derived SNAPTM Index • ARX-derived AER Index • AAI 1.5 : MLAEP derived

  7. What DoA monitoring technologies are available? • Newly introduced • EEG-derived cerebral state index • AAI 1.6 : EEG, MLAEP derived • PSI (patient state analyser) : quantitative EEG-derived • More established monitors • BIS (Bispectral Index Monitor, Aspect Medical Inc.,Newton, MA, USA) • Narcotrend index (Narcotrend Monitor, Schiller AG, Baar,Switzerland) • M-entropy module (GE Healthcare Helsinki, Finland) :State and Response Entropy (SE and RE)

  8. What DoA monitoring technologies are available? • Technical aspects • BIS

  9. Narcotrend M-entropy module

  10. What does the DoA monitor do? • Three differnetDoA monitors • Uses completely different algorithms (details are not published) • Basic principles (1)BIS based on a large volume of clinical data integrates several disparate descriptors of the EEG  single variable (2)Narcotrend index • EEG change during sleep  Automatic classification (based on visual assessment:originally related to sleep classification) • Applied to EEG change during anesthesia (stage A~F) • Statistical analysis  identify subsets of EEGs between stage A~F  finally further refined to numerical index between 0~100 (3)M-Entrophy module EEG : non-linear dynamics  quantify non-linear dynamics RE : calculated in 0 – 47 Hz, include EEG and EMG SE : 0 – 32 Hx , mainly include EEG

  11. Validation of DoA monitoring • Recovery time • Ganand colleagues • multicentre, randomized trial • 302 pts : propofol-alfentanil-nitrous oxide • Routine traditional care(age, health status, BP, HR)vsBIS minitoring • BIS monitoring : reduction in propofol administration, earlier recovery • Several trials : no substantial effect • Important issue by this series of studies • Meaningful reduction in recovery time  reduction in anesthetic drug administration • Short-acting drug (such as desflurane )  already rapid recovery time

  12. Validation of DoA monitoring • Definitive studies • Several large-scale studies : whether DoA monitoring can reduce the risk of awareness • Ekman and colleagues • before-and-after comparison 4945 patients(BIS monitor) vs 7826 patients • significant 5-fold reduction in risk, 0.04% vs 0.18%, P=0.038. • Myles and co-workers • A randomized, double-blind, multicentre trial • in 2643 adult patients at high risk of awareness • BIS-guided anaesthesiavsroutine care • a blinded observer for awareness at 2–6 h, 24–36 h, and 30 days after surgery • 2 reports of awareness in the BIS-guided group • 11 reports in the routine care group • P=0.022. BIS-guided anaesthesia reduce the risk of awareness by 82%

  13. DoA monitors : what’s next? • Future advaces in both anesthetic technology and pharmacology  increase overall quality of anesthesia • DoA monitor : important role • Economic decision • Cost-benefit anaysis need to be done • Routine awareness monitoring (about £30 million : UK health care) vs • reduction in drug usage, recovery times, Cx, hopital day • Awareness still occur in pt with DoA monitoring  failure of monitoring algorithm or artifact detetion  some pt condition  human error • Require further study

  14. DoA monitors : what’s next? • Aim during anesthesia or sedation • Without risk of awarness, hemodynamic instability, respiratory depression • Achieve and maintain adequate DoA • Large inter-individual variability  difficult to quantify clinical/phamacological effect • Recently Improved understanding of pharmacokinetics and pharmacodynamics  TCI , end-tidal controlled inhaled administration • DoA monitor : future anesthetic advisory and feedback system  total coverage of the dose-reponse relation • Such systems might help anaesthetist • Optimizing the titration of drug administration without overshoot • Controlling physiologic function • Guiding monitoring variables

More Related